FierceBiotech2d
Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small cell lung cancer—which the company described as the first treatment ...
Seeking Alpha2d
NovoCure: There Is Still More Upside
On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment, which resulted in positive price action. The lung cancer market will significantly increase NovoCure's scale ...
Yahoo Finance2d
Novocure shares soar 33% as FDA approves lung cancer treatment
Investing.com -- Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer.
Yahoo Finance2d
NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?
NovoCure (NVCR) shares ended the last trading session 10.7% higher at $17.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.
Investing2d
NovoCure stock upgraded to buy, price target set on recent FDA approval
On Tuesday, H.C. Wainwright upgraded shares of NovoCure Ltd. (NASDAQ: NASDAQ:NVCR) from Neutral to Buy, setting a price target of $30.00. The upgrade followed the recent FDA approval of NovoCure's ...
Nasdaq3d
NovoCure Breaks Above 200-Day Moving Average - Bullish for NVCR
In trading on Tuesday, shares of NovoCure Ltd (Symbol: NVCR) crossed above their 200 day moving average of $16.73, changing hands as high as $19.33 per share. NovoCure Ltd shares are currently ...
Business Insider3d
Buy Rating Affirmed for NovoCure as FDA Approval Expands Optune’s Market Potential
Larry Biegelsen, an analyst from Wells Fargo, maintained the Buy rating on NovoCure (NVCR – Research Report). The associated price target remains the same with $40.00. Larry Biegelsen has given ...
STAT3d
A controversial approval for Novocure’s device
From my colleague Adam Feuerstein: The FDA yesterday expanded the approval of Novocure’s Optune electrical field medical device to include the treatment of metastatic non-small cell lung cancer.
MarketWatch2d
Novocure shares surge on cancer treatment approval, and other movers
Novocure shares are surging 35% after the company said that the Food and Drug Administration had approved Optune Lua, its wearable treatment for certain types of lung cancer. Interactive Brokers ...
Benzinga.com2d
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
FDA approves NovoCure's Optune Lua for metastatic non-small cell lung cancer after platinum-based regimen. Optune Lua, combined with immunotherapy or docetaxel, extends overall survival by 3.3 months.
Business Wire3d
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
“Novocure is committed to extending survival in some of the most aggressive and difficult to treat cancers. The approval of Optune Lua brings a new and urgently needed option for people with ...